MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T

Objectives To compare contrast effects of gadobutrol with gadoterate meglumine for brain MRI in multiple sclerosis (MS) in a multicentre, randomized, prospective, intraindividual study at 3 T. Methods Institutional review board approval was obtained. Patients with known or suspected active MS lesion...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 2016-03, Vol.26 (3), p.820-828
Main Authors: Saake, Marc, Langner, Soenke, Schwenke, Carsten, Weibart, Marina, Jansen, Olav, Hosten, Norbert, Doerfler, Arnd
Format: Article
Language:English
Subjects:
Adult
Contrast agents
Contrast Media
Diagnostic Radiology
Female
Humans
Imaging
Internal Medicine
Interventional Radiology
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Male
Medicine
Medicine & Public Health
Meglumine
Multiple sclerosis
Multiple Sclerosis - pathology
Nervous system
Neuroradiology
Organometallic Compounds
Prospective Studies
Radiology
Reproducibility of Results
Review boards
Sensitivity and Specificity
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To compare contrast effects of gadobutrol with gadoterate meglumine for brain MRI in multiple sclerosis (MS) in a multicentre, randomized, prospective, intraindividual study at 3 T. Methods Institutional review board approval was obtained. Patients with known or suspected active MS lesions were included. Two identical MRIs were performed using randomized contrast agent order. Four post-contrast T1 sequences were acquired (start time points 0, 3, 6 and 9 min). If no enhancing lesion was present in first MRI, second MRI was cancelled. Quantitative (number and signal intensity of enhancing lesions) and qualitative parameters (time points of first and all lesions enhancing; subjective preference regarding contrast enhancement and lesion delineation; global preference) were evaluated blinded. Results Seventy-four patients (male, 26; mean age, 35 years) were enrolled in three centres. In 45 patients enhancing lesions were found. Number of enhancing lesions increased over time for both contrast agents without significant difference (median 2 for both). Lesions signal intensity was significantly higher for gadobutrol ( p  
ISSN:0938-7994
1432-1084
DOI:10.1007/s00330-015-3889-7